Interim Report January - September 2007 Tripep AB (publ.)

Interim Report January - September 2007  Tripep AB (publ.)

•	Research and development costs amounted to SEK 13.3 million
•	The loss after tax was SEK -21.7 million
•	Earnings per share were SEK -0.45
•	The company had no net sales for the period
•	Tripep has received all requisite permits for starting a clinical study of
ChronVac-C® on patients with chronic Hepatitis C virus infection. The study is
scheduled to start in October 2007
•	The research on the combination of ChronVac-C® and Inovio's DNA Delivery
System (DDS) technology was presented at the 14th International Symposium on
Hepatitis C Virus & Related Viruses in Glasgow on 9-13 September 2007

	       Events after the end of the reporting period
•	After the end of the reporting period, Tripep announced that it had signed a
Letter of Intent with Inovio Inc. of San Diego regarding the joint development
of ChronVac-B, a therapeutic vaccine against chronic Hepatitis B viral infection



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .